FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening
While more than one third of these top fund managers are outperforming this year, four of them stand out from the rest given their ability to outperform the market over almost all time periods.
More than a dozen analyst-approved foreign large-cap funds own these names.
While a majority of our top fund managers are outperforming this year, five of them truly stand out from the rest given their ability to outperform the market over all time periods.
Brand recognition and product innovation keep the firm's moat wide.
This year's list contains the 1998 and 2008 winners of the award.
This fund's comeback from the financial crisis has been balky, but it still has promise.
The five biotech ETFs have very different portfolios with markedly different performance.